Gujarat Themis Biosyn Ltd

💊 Gujarat Themis Biosyn Acquires Sanofi Portfolio Spanning 55+ Countries

• Acquired 13 anti-tuberculosis and anti-infective branded generic products from Sanofi

• Portfolio has presence in over 55 countries across Europe, Middle East, and Africa

• Portfolio net sales were approximately €62 million in 2025

• Previous sales were €66 million in FY23 and €67 million in FY24

• Total deal consideration is €158 million, payable in cash upon closing

• Acquisition is asset-light—includes brands, marketing authorizations, and inventory only

• Expands GTBL’s global generic pharmaceuticals platform and international footprint